A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases

Shmuel Odes, Dan Greenberg

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

The treatment of inflammatory bowel disease with standard therapy fails to control the disease in many patients. Biologic therapy has an increasing role in altering the natural history of Crohn’s disease and ulcerative colitis, and is improving patient prognosis. However, indications for treatment and issues with drug costs and value for money remain unclear. Also, when to perform early intervention with biologic agents is at present unclear. We performed an extensive literature search and review to address these issues. The biologics provide better care for many patients. The choice of biologic agent, the indications for its use, the switch between agents, and the considerations of cost are outlined, with a view to guiding the treating physician in managing these cases. Outstanding issues and anticipated future developments are defined.

Original languageEnglish
Pages (from-to)431-443
Number of pages13
JournalClinicoEconomics and Outcomes Research
Volume6
DOIs
StatePublished - 8 Oct 2014

Keywords

  • Biologic therapy
  • Cost-effectiveness
  • Crohn’s disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Fingerprint

Dive into the research topics of 'A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases'. Together they form a unique fingerprint.

Cite this